مهندسی و تولید آنزیم نوترکیب ریبونوکلئاز پانکراس گاوی (RNase A) به عنوان یک پتانسیل دارویی

 

References

Akbari B, Farajnia S, Ahdi Khosroshahi S et al. (2017) Immunotoxins in cancer therapy: Review and update. Int Rev Immunol 36, 207-219.

Ardelt W, Ardelt B, Darzynkiewicz Z (2009) Ribonucleases as potential modalities in anticancer therapy. Eur J Pharmacol 625, 181-189.

Borriello M, Laccetti P, Terrazzano G et al. (2011) A novel fully Human antitumour immunoRNase targeting ErbB2-positive tumours. Br J Cancer 104, 1716-1723.

Cuchillo CM, Nogués MV, Raines RT (2011) Bovine pancreatic ribonuclease: fifty years of the first enzymatic reaction mechanism. Biochem 50, 7835-7841.

Dickson KA, Haigis MC, Raines RT (2005) Ribonuclease inhibitor: structure and function. Prog Nucleic Acid Res Mol Biol 80, 349-374.

Findlay D, Herries DG, Mathias AP et al. (1961) The active site and mechanism of action of bovine pancreatic ribonuclease. Nature 190, 781–784.

Genscript, Piscataway, NJ, USA (http://www.genscript.com/cgi-bin/tools/rare_codon_analysis).

Gotte G, Laurents DV, Merlino A et al. (2013) Structural and functional relationships of natural and artificial dimeric bovine ribonucleases: new scaffolds for potential antitumor drugs. FEBS Lett 587, 3601-3608.

Gotte G, Menegazzi M (2019) Biological activities of secretory RNases: Focus on their oligomerization to design antitumor drugs. Front Immunol 10, 2626.

Johnson RJ, McCoy JG, Bingman CA et al. (2007) Inhibition of human pancreatic ribonuclease by the human ribonuclease inhibitor protein. J Mol Biol 368, 434-449.

Jordaan S, Akinrinmade OA, Nachreiner T et al. (2018) Updates in the development of immunoRNases for the selective killing of tumor cells. Biomedicines 6, 28.

Kimiz-Gebologlu I, Gulce-Iz S, Biray-Avci C (2018) Monoclonal antibodies in cancer immunotherapy. Mol Biol Rep 45, 2935‐2940.

Lee I (2008) Ranpirnase (Onconase), a cytotoxic amphibian ribonuclease, manipulates tumour physiological parameters as a selective killer and a potential enhancer for chemotherapy and radiation in cancer therapy. Expert Opin Biol Ther 8, 813-827.

Li M, Liu ZS, Liu XL et al. (2017) Clinical targeting recombinant immunotoxins for cancer therapy. Onco Targets Ther 10, 3645‐3665.

Mohammadabadi MR, Mozafari MR (2019) Enhanced efficacy and bioavailability of thymoquinone using nanoliposomal dosage form. J Drug Delivery Sci Technol 47, 445–453.

Pucci C, Martinelli C, Ciofani G (2019) Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience 13, 961.

Raines RT (2004) Active Site of Ribonuclease A. In: Artificial Nucleases (1st edn). Zenkova MA (eds). Springer, Berlin, Heidelberg. pp. 19-32.

Rutkoski TJ, Kink JA, Strong LE (2010) Antitumor activity of ribonuclease multimers created by site-specific covalent tethering. Bioconjug Chem 21, 1691-1702.

Schirrmann T, Frenzel A, Linden L et al. (2014) Evaluation of human pancreatic RNase as effector molecule in a therapeutic antibody platform. MAbs 6, 367–380.

Sun M, Sun L, Sun D et al. (2018) Targeted delivery of immuno-RNase may improve cancer therapy. Cancer Cell Int 18, 58.

Taherian E, Mohammadi E, Jahanian-Najafabadi A et al. (2019) Cloning, optimization of periplasmic expression and purification of recombinant granulocyte macrophage-stimulating factor in Escherichia coli BL21 (DE3). Adv Biomed Res 8, 71.

PyMol Software (2016) The PyMOL molecular graphics system, Version 1.8 Schrödinger, LLC, NY, USA.

World Health Organization (2018) Latest global cancer data: International Agency for Research on Cancer. Geneva, Switzerland.